Spinal muscular atrophy (SMA) drug Spinraza has been the brightest star in Biogen's constellation lately. Sales for Spinraza soared 17% year over year in the third quarter. While the growth rate for the blockbuster drug has slowed, predictions that Spinraza would lose significant market share to Novartis ' Zolgensma haven't come true so far.